Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )

NCT07390604 | Completed

• 1 other identifier: 2025-03Obs-CHRMT
• Study Type: observational
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (\>200 nmol/L) who had a history of cardiovascular disease and notable thromboembolic events.

Conditions

Lipoprotein-apheresis; Double-filtration Plasmapheresis; Hemodialysis Complication; End Stage Chronic Renal Failure; Lipoprotein(a)

Outcome Measures

Primary Outcomes (1)

• serum Lp(a) concentration (nmol/L), on routine venous blood sampling

  Before and after each DFPP session (repeated measures) during the study period

  up to 15 months after inclusion

Secondary Outcomes (5)

• serum LDL and serum triglycerides concentration (g/L), on routine venous blood sampling

  up to 15 months after inclusion

• serum triglycerides concentration (g/L), on routine venous blood sampling

  up to 15 months after inclusion

• cardiovascular or thromboembolic events

  during all the study period: up to 15 months after inclusion

• Hemodynamic status:blood pressure

  up to 15 months after inclusion

• Hemodynamic status: ultrafiltration rate

  up to 15 months after inclusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

chronic Hemodialsisi patients

You may qualify if:

• Chronic hemodialysis patients with elevated Lp(a) levels (\>200 nmol/L) and a history of cardiovascular disease and/or thromboembolic events who underwent DFPP sessions as part of their management

You may not qualify if:

• Patients with progressive, active disease, presenting with severe general deterioration and a limited life expectancy
• Patients presenting with hemodynamic instability
• Patients presenting with acute kidney diseases.

Sponsors & Collaborators

• Centre Hospitalier Régional Metz-Thionville: lead

Study Sites (1)

CHR Metz-Thionville Hopital de Mercy

Metz, 57085, France

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Zead TUBAIL, MD

  CHR Metz-Thionville Hopital de Mercy

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 14, 2026
• First Posted: February 5, 2026
• Study Start: July 1, 2025
• Primary Completion: September 30, 2025
• Study Completion: December 31, 2025
• Last Updated: February 5, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)